ClinicalTrials.gg
CompletedNCT01824251Updated Jan 20, 2016

Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

A Phase 3 interventional study of NPB-01 in Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Nihon Pharmaceutical Co., Ltd. Completed at 1 site in Japan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2016-01-20.

Sponsored by Nihon Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan — 7 open to participants now, 9 under way, 8 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Japan.

Enrollment
14th of 16
49 · median 160
Started
2013
the only one that year
Phase 3
12 of 16
6 open now
Registered
3rd of 16
by date
Lead sponsor
1 of 16
Nihon Pharmaceutical Co., Ltd

Among the 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan, this one is the 14th largest by enrollment, is the only one that started in 2013, is one of 12 in phase 3, and was the 3rd registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

7 of the 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan, or all of them as a file.
02

Study summary

Patients diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy were confirmed based on the European Federation of Neurological Societies/ Peripheral. Nerve Society Guideline. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Subsequently, patients receive NPB-01 1g/kg every 3weeks and evaluate the Inflammatory Neuropathy Cause and Treatment(INCAT) score and INCAT sensory sumscore(ISS) et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyneuropathy

Keywords

  • IVIG in Chronic Inflammatory Demyelinating Polyneuropathy
  • Patients with Chronic Inflammatory Demyelinating Polyneuropathy
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Patients with progressive or relapsing motor and sensory dysfunction of more than one limb resulting from neuropathy within 2 months prior to the date is obtained.
    1. Patients who INCAT score between 2-9. (If the INCAT score is 1 in upper limb, the INCAT score of 2 must be exclusively from leg disability to qualify.)
    1. Patients who need high-dose intravenous immunoglobulin therapy.
    1. Patients who continued treatment for CIDP without addition or increase at 30 days before informed consent.
    1. Patients with greater than or equal to twenty years old at informed consent.

Exclusion criteria

Exclusion Criteria:

    1. Patients with evidence of myelopathy or demyelination of central nerve
    1. Patients with evidence of stroke, central nerve system trauma, or persistent neurological deficits due to peripheral neuropathy from other causes(diabetic neuropathy, IgM paraproteinaemia, uraemic neuropathy, toxic neuropathy, hereditary neuropathy)
    1. Patients with evidence of neuropathy or alcoholic neuropathy or vitamin deficiency neuropathy due to myeloma, lymphoma, sarcoidosis, systemic lupus erythematosus, , vasculitis, Crow-Fukase syndrome, Sjögren syndrome.
    1. Patients with multifocal motor neuropathy.
    1. Patients treated with plasmapheresis at 3 months before .
    1. Patients treated with rituximab at 6 months before informed consent.
    1. Patients treated with high-dose intravenous immunoglobulin(greater than or equal to 1g/kg) at 8 weeks before informed consent.
    1. Patients treated with intravenous immunoglobulin at 3 weeks before informed consent.
    1. Patients with history of shock or for NPB-01.
    1. Patients with IgA deficiency.
    1. Patients with malignancy at informed consent.
    1. Patients with impaired liver function.
    1. Patients with impaired renal function.
    1. Patients with cerebro- or cardiovascular disorders.
    1. Patients with high risk of thromboembolism.
    1. Patients with hemolytic/hemorrhagic anemia.
    1. Patients with decreased cardiac function.
    1. Patients with decreased .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    NPB-01

    Intravenous immunoglobulin

    Drug: NPB-01

Interventions

  • DrugNPB-01

    Also known as: Intravenous immunoglobulin

06

What researchers measure

Primary outcomes

  1. proportion of patients with more than 1point improvement in the INCAT score relative to baseline at 28weeks.

    Time frame: 28weeks

  2. proportion of patients with more than 1point exacerbation in the INCAT score relative to 28weeks at 52weeks.

    Time frame: 52weeks

Secondary outcomes

  1. INCAT score

    Time frame: 1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks

  2. ISS

    Time frame: 1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks

  3. maximum grip strength

    Time frame: 1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks

  4. Medical Research Council(MRC) sum score

    Time frame: 1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks

  5. the amplitude of the compound muscle action potential of the most severely affected motor nerve

    Time frame: 1,4,28,52weeks

07

Study locations

1 site
  • Nihon Pharmaceutical Co., Ltd
    Osaka, Japan
08

References and documents

Publications

  • Kuwabara S, Mori M, Misawa S, Suzuki M, Nishiyama K, Mutoh T, Doi S, Kokubun N, Kamijo M, Yoshikawa H, Abe K, Nishida Y, Okada K, Sekiguchi K, Sakamoto K, Kusunoki S, Sobue G, Kaji R; Glovenin-I CIDP Study Group. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):832-838. doi: 10.1136/jnnp-2017-316427. Epub 2017 Aug 2. PubMed 28768822 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2013
First posted
Apr 4, 2013
Start
Apr 2013
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Last update
Jan 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01824251
Lead sponsor
Nihon Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Apr 4, 2013
Start date
Apr 2013
Primary completion
Sep 2015
Completion
Sep 2015
Last update
Jan 20, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion